FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2037276396> ?p ?o ?g. }

• W2037276396 endingPage "219" @default.
• W2037276396 startingPage "214" @default.
• W2037276396 abstract "Investigation of serum markers which could be used in the malignancy prediction of adnexal masses.Vascular endothelial growth factor (VEGF), interleukin 6 (IL-6), leptin, C-reactive protein (CRP), creatine-kinase-MB (CK-MB) and cancer antigen 15-3 (CA 15-3) levels were determined prospectively in serum samples that were obtained from patients who underwent surgery for an adnexal mass and who were referred to Istanbul University, Faculty of Medicine, Department of Obstetrics and Gynecology, between 2009 and 2011, and then were compared with the serum samples of completely healthy outpatient patients as a control group. Based onto the ovarian cancer status, cases were divided into four groups: 13 patients were included in the early-stage malignant group, 12 patients were included in the advanced-stage malignant group, 25 in the benign group and 19 in the healthy control group. Patients with only epithelial ovarian cancer were included into the cancer group. Ethics Commitee approval was obtained for this study. The budget was supported by the Istanbul University Scientific Research Projects Unit.RESULTS RELATED WITH SENSITIVITY, SPECIFICITY, POSITIVE PREDICTIVE VALUE (PPV), NEGATIVE PREDICTIVE VALUE (NPV) AND ODDS RATIO (OR), RESPECTIVELY, AND THE FOLLOWING VALUES WERE CALCULATED: 48%, 95%, 92%, 59% and +OR 9.6 -OR 0.5 for CA; 15-3; 52%, 75%, 72%, 55%, +OR 2.08 -OR 0.64 for leptin; 72%, 70%, 75%, 66% 2.4-0.5 for IL-6; 24%, 80%, 60%, 45%, 1.2-0.92 for VEGF; 68%, 30%, 55%, 43%, 0.97-1.06 for CRP; and 8%, 70%, 25%, 38%, 026-1.31 for CK-MB.CA 15-3, IL-6, Leptin, VEGF and CRP were effective in the prediction of benign and malignant masses; however they may be more suitable in selected cases as they have a limited use because of their inadequate potential regarding sensitivity and specificity.Adneksiyel kitlelerde malignite ayrımında kullanılabilecek serum markerlarının araştırılması.İstanbul Üniversitesi İstanbul Tıp Fakültesi Kadın Hastalıkları ve Doğum Anabilim Dalı’nda 2009–2011 yılları arasında prospektif olarak, adneksiyel kitle endikasyonu ile opere olan hastalardan alınan serum örneklerinde vascular endotelial growth factor (VEGF), interlökin 6 (IL-6), leptin, C-reaktif protein (CRP), kreatin kinaz-MB (CK-MB) ile kanser antijeni 15-3 (CA 15-3) düzeyleri belirlendi ve kontrol grubu olan tamamen sağlıklı poliklinik hastalarının serum örnekleriyle karşılaştırıldı. Olgular over kanseri durumuna göre 4 grupta toplandı: 13 olgu erken evre malign, 12 olgu ileri evre malign, 25 olgu benign, 19 olgu sağlıklı kontrol grubunda yer aldı. Over kanseri grubunda sadece epitelyal over kanseri olan olgular çalışmaya dahil edildi. Çalışma için etik kurul onayı alındı ve bütçe ise İstanbul Üniversitesi Bilimsel Araştırma Projeleri Birimi tarafından desteklendi.Belirteçlerin duyarlılık, özgüllük, pozitif prediktif değer (PPD), negatif prediktif değer (NPD) ve odds ratio (OR) sonuçlarına bakıldığında CA 15-3 için sırasıyla %48, %95, %92, %59 ve +OR 9.6 −OR 0.5; leptin için sırasıyla %52, %75, %72, %55, +OR 2.08 −OR 0.64; IL-6 için %72, %70, %75, %66 2.4-0.5; VEGF için %24, %80, %60, %45, 1.2-0.92; CRP için %68, %30, %55, %43, 0.97–1.06; CK-MB için %8, %70, %25, %38, 026–1.31 değerleri hesaplandı.CA 15-3, IL-6, Leptin, VEGF ve CRP benign-malign over tümörü ayrımında etkin bulundu ancak duyarlılık ve özgüllükleri yeteri kadar kuvvetli olmadığı için rutinde kullanımı kısıtlı olup seçilmiş vakalarda kullanımı uygun olabilir." @default.
• W2037276396 created "2016-06-24" @default.
• W2037276396 creator A5034413234 @default.
• W2037276396 creator A5050571116 @default.
• W2037276396 creator A5056560044 @default.
• W2037276396 creator A5062082369 @default.
• W2037276396 creator A5063130274 @default.
• W2037276396 creator A5065233028 @default.
• W2037276396 date "2011-11-01" @default.
• W2037276396 modified "2023-10-18" @default.
• W2037276396 title "Determination of serum CRP, VEGF, Leptin, CK-MB, CA-15-3 and IL-6 levels for malignancy prediction in adnexal masses" @default.
• W2037276396 cites W1583772274 @default.
• W2037276396 cites W1951029407 @default.
• W2037276396 cites W1969257875 @default.
• W2037276396 cites W1998258610 @default.
• W2037276396 cites W2001866306 @default.
• W2037276396 cites W2021499511 @default.
• W2037276396 cites W2027138920 @default.
• W2037276396 cites W2030214755 @default.
• W2037276396 cites W2037550429 @default.
• W2037276396 cites W2051639596 @default.
• W2037276396 cites W2058694408 @default.
• W2037276396 cites W2072347219 @default.
• W2037276396 cites W2085189353 @default.
• W2037276396 cites W2096116951 @default.
• W2037276396 cites W2105112691 @default.
• W2037276396 cites W2138482047 @default.
• W2037276396 cites W2144011801 @default.
• W2037276396 cites W2150087209 @default.
• W2037276396 cites W2150482382 @default.
• W2037276396 cites W2155150395 @default.
• W2037276396 cites W2166703150 @default.
• W2037276396 cites W2245111413 @default.
• W2037276396 cites W2395390878 @default.
• W2037276396 cites W3012574199 @default.
• W2037276396 doi "https://doi.org/10.5152/jtgga.2011.54" @default.
• W2037276396 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3939252" @default.
• W2037276396 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24591997" @default.
• W2037276396 hasPublicationYear "2011" @default.
• W2037276396 type Work @default.
• W2037276396 sameAs 2037276396 @default.
• W2037276396 citedByCount "7" @default.
• W2037276396 countsByYear W20372763962013 @default.
• W2037276396 countsByYear W20372763962017 @default.
• W2037276396 countsByYear W20372763962018 @default.
• W2037276396 countsByYear W20372763962021 @default.
• W2037276396 countsByYear W20372763962023 @default.
• W2037276396 crossrefType "journal-article" @default.
• W2037276396 hasAuthorship W2037276396A5034413234 @default.
• W2037276396 hasAuthorship W2037276396A5050571116 @default.
• W2037276396 hasAuthorship W2037276396A5056560044 @default.
• W2037276396 hasAuthorship W2037276396A5062082369 @default.
• W2037276396 hasAuthorship W2037276396A5063130274 @default.
• W2037276396 hasAuthorship W2037276396A5065233028 @default.
• W2037276396 hasBestOaLocation W20372763961 @default.
• W2037276396 hasConcept C10885799 @default.
• W2037276396 hasConcept C121608353 @default.
• W2037276396 hasConcept C126322002 @default.
• W2037276396 hasConcept C167734588 @default.
• W2037276396 hasConcept C2776914184 @default.
• W2037276396 hasConcept C2777025900 @default.
• W2037276396 hasConcept C2779234561 @default.
• W2037276396 hasConcept C2779399171 @default.
• W2037276396 hasConcept C2780427987 @default.
• W2037276396 hasConcept C2780613262 @default.
• W2037276396 hasConcept C2781195455 @default.
• W2037276396 hasConcept C29456083 @default.
• W2037276396 hasConcept C2992389814 @default.
• W2037276396 hasConcept C3020110884 @default.
• W2037276396 hasConcept C511355011 @default.
• W2037276396 hasConcept C54355233 @default.
• W2037276396 hasConcept C71924100 @default.
• W2037276396 hasConcept C86803240 @default.
• W2037276396 hasConcept C90924648 @default.
• W2037276396 hasConceptScore W2037276396C10885799 @default.
• W2037276396 hasConceptScore W2037276396C121608353 @default.
• W2037276396 hasConceptScore W2037276396C126322002 @default.
• W2037276396 hasConceptScore W2037276396C167734588 @default.
• W2037276396 hasConceptScore W2037276396C2776914184 @default.
• W2037276396 hasConceptScore W2037276396C2777025900 @default.
• W2037276396 hasConceptScore W2037276396C2779234561 @default.
• W2037276396 hasConceptScore W2037276396C2779399171 @default.
• W2037276396 hasConceptScore W2037276396C2780427987 @default.
• W2037276396 hasConceptScore W2037276396C2780613262 @default.
• W2037276396 hasConceptScore W2037276396C2781195455 @default.
• W2037276396 hasConceptScore W2037276396C29456083 @default.
• W2037276396 hasConceptScore W2037276396C2992389814 @default.
• W2037276396 hasConceptScore W2037276396C3020110884 @default.
• W2037276396 hasConceptScore W2037276396C511355011 @default.
• W2037276396 hasConceptScore W2037276396C54355233 @default.
• W2037276396 hasConceptScore W2037276396C71924100 @default.
• W2037276396 hasConceptScore W2037276396C86803240 @default.
• W2037276396 hasConceptScore W2037276396C90924648 @default.
• W2037276396 hasIssue "4" @default.
• W2037276396 hasLocation W20372763961 @default.
• W2037276396 hasLocation W20372763962 @default.
• W2037276396 hasLocation W20372763963 @default.
• W2037276396 hasOpenAccess W2037276396 @default.

• next